ME Therapeutics is a biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics that reprogram immune cells in vivo to directly recognize cancer cells and activate the body’s immune response against cancer.
Patent Cooperation Treaty filed in February 2018 on composition and use of lead G-CSF antibodies
Chinese patent granted in 2023 for G-CSF antibody candidate
U.S. patent granted in 2025 for G-CSF antibody candidate
INVESTMENT OPPORTUNITY
We believe that myeloid targeted drugs have great potential to improve the efficacy ofcheckpoint inhibitors creating a potentially large financial opportunity for our investors.
